Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
FULCRUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Di | H.C. Wainwright upgrades Fulcrum Therapeutics stock rating on promising SCD data | 1 | Investing.com | ||
Di | Fulcrum Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
Di | Fulcrum Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
Di | Fulcrum Therapeutics GAAP EPS of -$0.28 beats by $0.01 | 1 | Seeking Alpha | ||
Di | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | 85 | GlobeNewswire (Europe) | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
Di | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease | 46 | GlobeNewswire (Europe) | - Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% - Evidence... ► Artikel lesen | |
Mo | Fulcrum Therapeutics-Aktie schießt vor Daten zu Sichelzellkrankheit in die Höhe | 9 | Investing.com Deutsch | ||
Mo | Fulcrum Therapeutics stock soars ahead of sickle cell trial data | 3 | Investing.com | ||
Mo | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease | 2 | GlobeNewswire (USA) | ||
11.07. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 100 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
27.06. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
11.06. | Fulcrum Therapeutics auf Goldman Sachs Konferenz: Strategische Updates und Zukunftspläne | 3 | Investing.com Deutsch | ||
06.06. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 135 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
29.05. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings | 1 | GlobeNewswire (USA) | ||
24.05. | Leerink raises Fulcrum Therapeutics stock to Outperform | 3 | Investing.com | ||
09.05. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 184 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
01.05. | Fulcrum Therapeutics GAAP EPS of -$0.28 beats by $0.01 | 3 | Seeking Alpha | ||
01.05. | Fulcrum Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
01.05. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | Uncovering Potential: Fulcrum Therapeutics' Earnings Preview | 2 | Benzinga.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 44,180 | -0,24 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
CUREVAC | 4,720 | +0,90 % | CureVac ÜBERRASCHT Anleger: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
MODERNA | 28,575 | +1,04 % | Aktie von Moderna heute am Aktienmarkt gefragt (28,74 €) | An der US-amerikanischen Börse notiert der Anteilsschein von Moderna derzeit etwas fester. Zuletzt zahlten Investoren für das Papier 28,74 Euro. Die Aktie von Moderna verzeichnet zur Stunde einen Wertanstieg... ► Artikel lesen | |
VALNEVA | 3,278 | +0,06 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen | |
AMGEN | 264,60 | +0,72 % | Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue? | ||
NOVAVAX | 6,180 | +1,76 % | Novavax, Inc.: Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study | Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose... ► Artikel lesen | |
STRYKER | 349,40 | +0,75 % | Stryker's Inari Medical Launches Next-Gen InThrill System For Small Vessel Thrombectomy | WASHINGTON (dpa-AFX) - Stryker's (SYK) Inari Medical has unveiled the next-generation InThrill Thrombectomy System, marking the first dedicated solution for small vessel and arteriovenous or... ► Artikel lesen | |
BIOGEN | 112,00 | +1,13 % | Biogen's ZURZUVAE Wins EMA Panel Backing For Postpartum Depression Treatment | WESTON (dpa-AFX) - Biogen Inc. (BIIB), Friday announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has backed marketing authorization for ZURZUVAE... ► Artikel lesen | |
ILLUMINA | 93,66 | -0,50 % | 12 Analysts Assess Illumina: What You Need To Know | ||
CRISPR THERAPEUTICS | 52,00 | +0,97 % | The 3 Things That Matter for CRISPR Therapeutics Now | ||
REGENERON PHARMACEUTICALS | 490,20 | +1,43 % | $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today | ||
SANGAMO THERAPEUTICS | 0,499 | +1,18 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
VIKING THERAPEUTICS | 29,460 | +3,37 % | Viking Therapeutics nach Zahlen: Geht die Rallye weiter? | Seit meinem letzten Update läuft die Aktie von Viking Therapeutics immer höher. Die Rallye des Biotechs könnte sich nach dem Quartalsbericht von dieser Woche fortsetzen. Sektor erholt sich - Viking... ► Artikel lesen | |
EDITAS MEDICINE | 2,289 | +2,28 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 16,085 | +17,37 % | SAREPTA THERAPEUTICS: Volatile Erholung. | Die Aktie des Biotechunternehmens aus Cambridge, Massachusetts, erholte sich spaktakulär von dem am 18. Juli ausgelösten Kurseinbruch. Nach (leberbedingten) Todesfällen mit vermutetem Zusammenhang zu... ► Artikel lesen |